OPHLF Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 20:33):

Stats
Dagens volum	500.00
Gjennomsnittsvolum	498.00
Markedsverdi	6.80B
EPS	$0 ( 2024-01-30 )
Neste inntjeningsdato	( $0.00213 ) 2024-06-20
Last Dividend	$37.00 ( 2023-03-30 )
Next Dividend	$0 ( N/A )
P/E	8.93
ATR14	$0 (0.00%)

Ono Pharmaceutical Co., Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Ono Pharmaceutical Co., Økonomi

Annual	2023
Omsetning:	$447.19B
Bruttogevinst:	$337.13B (75.39 %)
EPS:	$230.85

FY	2023
Omsetning:	$447.19B
Bruttogevinst:	$337.13B (75.39 %)
EPS:	$230.85

FY	2022
Omsetning:	$361.36B
Bruttogevinst:	$267.85B (74.12 %)
EPS:	$162.19

FY	2021
Omsetning:	$309.28B
Bruttogevinst:	$223.71B (72.33 %)
EPS:	$151.11

Financial Reports:

No articles found.

Ono Pharmaceutical Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$33.00 (N/A)	$0 (N/A)	$37.00 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Ono Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.15 - Stable (22.99%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$18.00	2013-03-27
Last Dividend	$37.00	2023-03-30
Next Dividend	$0	N/A
Payout Date	2018-06-25
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	$444.50	--
Avg. Dividend % Per Year	0.00%	--
Score	3.53	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.15
Div. Directional Score	9.41	--

Next Divdend (Est)
(2024-07-18)

$0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

3.53

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
OSAGY	No Dividend Player	2023-06-16	Annually	0.00%
DAIUF	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
TXHPF	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
JARLF	Ex Dividend Knight	2023-08-17	Semi-Annually	0.00%
BDVSY	Ex Dividend Junior	2023-09-28	Annually	0.00%
RCBC	Ex Dividend Junior	2023-07-31	Quarterly	0.00%
ENGGY	Ex Dividend Knight	2023-07-03	Semi-Annually	0.00%
WBHC	Ex Dividend Junior	2023-06-29	Sporadic	0.00%
LDSCY	Ex Dividend Junior	2023-08-24	Quarterly	0.00%
CCFN	Ex Dividend Knight	2023-08-14	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.256	1.500	4.88	7.31	[0 - 0.5]
returnOnAssetsTTM	0.143	1.200	5.23	6.28	[0 - 0.3]
returnOnEquityTTM	0.166	1.500	9.26	10.00	[0.1 - 1]
payoutRatioTTM	0.291	-1.000	7.09	-7.09	[0 - 1]
currentRatioTTM	3.95	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.19	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.140	1.500	4.78	7.17	[0.2 - 2]
debtRatioTTM	0.00963	-1.500	9.84	-10.00	[0 - 0.6]
interestCoverageTTM	99.03	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	222.86	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	191.88	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0109	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.756	1.000	0.740	0.740	[0.2 - 0.8]
operatingProfitMarginTTM	0.329	1.000	5.41	5.41	[0.1 - 0.6]
cashFlowToDebtRatioTTM	12.35	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.559	0.800	9.61	7.69	[0.5 - 2]
Total Score				12.67

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	8.50	1.000	9.24	0	[1 - 100]
returnOnEquityTTM	0.166	2.50	9.53	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	191.88	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0233	1.500	9.42	0	[0 - 0.4]
operatingCashFlowPerShareTTM	222.86	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.291	1.500	7.09	-7.09	[0 - 1]
pegRatioTTM	0.00758	1.500	-3.28	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.213	1.000	7.18	0	[0.1 - 0.5]
Total Score				6.15

Ono Pharmaceutical Co.,

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.